Business Wire

Autolus Announces Appointment of Andrew J. Oakley as Senior Vice President and Chief Financial Officer

Del

Autolus Therapeutics Limited (to be reorganised as Autolus Therapeutics plc) (“Autolus”), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced the appointment of Andrew J. Oakley as its Senior Vice President and Chief Financial Officer, effective prior to the closing of Autolus’ planned initial public offering.

Dr. Christian Itin, Autolus’ Chairman and Chief Executive Officer, commented:

“We are delighted to welcome Andrew to Autolus. Andrew brings a wealth of international finance experience to Autolus, having been a CFO for public life science companies for more than 15 years. His proven ability to successfully manage growth is an excellent fit for Autolus and our drive to unlock the potential of T cell therapies in oncology.”

Andrew Oakley said:

“I am excited to join Autolus as Senior Vice President and Chief Financial Officer at this transformational stage in the company’s development. Autolus aims to be a leading global programmed T cell therapy company and I look forward to working with my new colleagues as we progress our programmed T cell therapies through development and towards commercialisation.”

Andrew joins Autolus from Sosei Group Corporation where he served as its executive vice president and chief financial officer since February 2017. Prior to that, he served as chief financial officer, company secretary and executive board member of Vectura Group plc from January 2015 to June 2016, as chief financial officer of NovImmune SA from March 2014 to November 2014 and as executive vice president and chief financial officer of Actelion Pharmaceuticals Ltd from January 2003 to August 2013. He has also held a senior finance role at Accenture, executive leadership positions in major multinational building material companies, and has spent several years as an equity analyst with banks in Australia, the United Kingdom and the United States.

Andrew holds a Bachelor of Economics degree from Macquarie University and an MBA from London Business School and has been a Member of the Australian Institute of Chartered Accountants since 1987.

About Autolus
Autolus is a private, clinical-stage biopharmaceutical company developing next-generation, programmed T cell therapies for the treatment of cancer. Using a broad suite of proprietary and modular T cell programming technologies, the company is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognise cancer cells, break down their defence mechanisms and eliminate these cells. Autolus has a pipeline of product candidates in development for the treatment of haematological malignancies and solid tumours.

For further information, please visit the company’s website at: www.autolus.com

Contact information

Investor Contact
S.A. Noonan Communications, LLC
Susan A. Noonan
212 966 3650
susan@sanoonan.com
or
Media Contact
JW Communications
Julia Wilson
+44 (0)7818 430877
juliawilsonuk@gmail.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

GHX Exhibiting at MEDICA 2018 – World Forum for Healthcare15.10.2018 08:00Pressemelding

Global Healthcare Exchange (GHX), a leader in cloud-based healthcare supply chain management solutions, will be exhibiting at the leading international trade fair for the medical sector, MEDICA 2018, in Düsseldorf, Germany between the 12th and 15th November, 2018. GHX provides a full range of intelligent eCommerce and supply chain solutions specifically designed for the complex world of healthcare. The organisation’s technology connects thousands of healthcare suppliers, manufacturers and distributors with hospitals and GPOs – as well as to Governments for reporting processes. GHX technology enables the right devices, equipment, services and medicines to flow efficiently through the European healthcare supply chain. MEDICA attendees are invited to visit GHX in Hall 16, Stand F20-2, to discover how the organisation’s deep commitment to the healthcare industry, unrivalled understanding of the sector and proactive approach to collaboration to develop best practice, ensures its technology

Intertops Poker satellite sending another winner to the Malta Poker Festival where €500K is guaranteed!15.10.2018 07:06Pressemelding

Intertops Poker is sending another online satellite tournament winner to play in the €500,000 guaranteed Malta Poker Festival Main Event that runs from November 1st – 6th at the Portamaso Casino. The $2,500 prize package covers the winner’s buy-in to the Malta Poker Festival Main Event, Day 1C. $500 toward travel expenses is included. The online champion will stay at the posh Hilton Hotel November 2 – 7th. The Intertops team will take them to an exclusive MPF VIP party. The Poker Manager at Intertops Poker, said: “The Malta Poker Festival is a brand new event but I am sure it will be a hit, and there is still chance for players to earn their seat at the tables for the main event. “The festival has it all; it is set in a stunning location, it is playing in a prestigious casino and it has a life-changing prize pot. So if you think you have what it takes to lift the trophy, sign-up for the satellite now. Satellites: To register, open the Intertops Poker lobby, click ‘Poker’ > ‘Tournaments

Results from Pradaxa® RE-SPECT ESUS® and RE-SPECT CVT® trials to be presented at the 11th World Stroke Congress15.10.2018 07:00Pressemelding

Boehringer Ingelheim today announced that primary results from two key trials, RE-SPECT ESUS® and RE-SPECT CVT®, will be presented at the upcoming World Stroke Congress in Montreal, Canada 17-20 October 2018. These primary analyses will contribute to the scientific community’s understanding of both disease states and the clinical profile of dabigatran etexilate (Pradaxa®). The results from RE-SPECT ESUS, the first randomised trial comparing dabigatran etexilate with acetylsalicylic acid (ASA) in any indication, will add further insight into the prevention of secondary stroke in patients with an embolic stroke of undetermined source (ESUS).1 As the first comparison to ASA, this trial will also offer further important insights into the clinical profile of dabigatran etexilate. RE-SPECT CVT will provide additional knowledge regarding treatment of patients with cerebral venous thrombosis (CVT).2 It is the first exploratory, prospective, randomised controlled study of any non-vitamin K anta

IFC and Alipay Announce 10x1000 Tech for Inclusion Programme to Inspire Technology Leaders in Emerging Markets15.10.2018 04:15Pressemelding

International Financial Corporation (“IFC”), a member of the World Bank Group, and Ant Financial Services Group (“Ant Financial”), the world’s leading tech company and the operator of Alipay, jointly announced the 10x1000 Tech for Inclusion programme at the 2018 Annual Meetings of the International Monetary Fund and the World Bank Group. The initiative will include a comprehensive programme that embraces interactivity and the exchange of ideas to provide training to 10,000 tech experts in emerging markets from both public and private sectors over the next 10 years. Alibaba Group founder and Executive Chairman Jack Ma said that the programme aims to build an interactive and open platform to increase support for tech leaders and skilled individuals who are working to alleviate poverty and make basic financial services more broadly accessible in Indonesia, which will be the first stop of the programme within emerging markets. “I believe that investing in people is investing for the future

Chugai Presents Results from Phase III Study of Satralizumab in NMOSD at ECTRIMS 201815.10.2018 03:00Pressemelding

Chugai Pharmaceutical Co., Ltd. (TOKYO:4519) announced that results from the phase III study of satralizumab (development code: SA237), SAkuraSky Study (NCT02028884), were presented at the Congress of European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) 2018 held in Berlin, Germany from October 10 to 12. Satralizumab is a humanized investigational recycling anti-IL-6 receptor monoclonal antibody for the treatment of neuromyelitis optica spectrum disorder (NMOSD), which currently has no approved treatments. “These positive pivotal results for satralizumab, showing a significant reduction in relapses in patients, are a significant positive step in the potential treatment of NMOSD,” said Dr. Takashi Yamamura, Director, Department of Immunology, National Institute of Neuroscience, National Center of Neurology and Psychiatry, Tokyo. “Many people with NMOSD are suffering from frequent relapses and often persistent motor dysfunction and loss of sensation, and end up r

Guidewire InsuranceSuite Positioned as a Leader in Gartner's Magic Quadrant for P&C Core Platforms, North America, for Second Consecutive Year14.10.2018 17:10Pressemelding

GUIDEWIRE CONNECTIONS 2018–- Guidewire Software, Inc. (NYSE: GWRE), provider of the industry platform Property and Casualty (P&C) insurers rely upon, today announced that Guidewire InsuranceSuite™ has been recognized as a Leader in Gartner, Inc.'s “Magic Quadrant for P&C Core Platforms, North America 1 .” InsuranceSuite comprises essential core systems based on a common technology platform covering the P&C insurance lifecycle including underwriting, policy, billing, and claims management. It was positioned highest on the ability to execute axis and furthest on the completeness of vision axis in the report. The report can be viewed here. “While many vendors are playing to specific strengths, market leaders are expanding the scope of their capabilities with a growing emphasis on broader ecosystems with partners accessible through prebuilt integration in an app-store-like venue. As the number of ecosystem partners grows, this promises customers quicker access to a range of new capabilitie